Headcase protein homolog (HECA)

Headcase protein homolog (HECA) is a conserved cell cycle regulator and tumor suppressor, first characterized in Drosophila (as 'headcase') and in humans. HECA modulates cell cycle progression, slows cell division, and encourages cell differentiation, especially during adult morphogenesis and in cancer cell lines[5]. Functionally, HECA localizes to ribonucleoprotein granules, where it contributes to granule formation, translation control, and cellular stress protection by regulating reactive oxygen species and protein synthesis[3][4]. In cancer, HECA expression is often reduced, correlating with increased cell proliferation and de-differentiation; in head and neck cancer, overexpression slows cell division and induces cell cycle arrest in G2/M phase[5]. HECA is not currently known to be a direct drug target, but it is mechanistically important in malignancy, cell adhesion, and stress granule biology[3][4][5][7]. Studies establishing HECA as a tumor suppressor in oral squamous cell carcinoma and detailing its cell cycle arrest role[5][7]. Human and Drosophila HECA is a component of RNP granules, involved in translational regulation and stress granule formation[3][4]. Alterations in HECA protein are associated with multiple cancers, suggesting a possible role as a biomarker for patient selection or disease progression[5]. HECA is not a classic receptor, enzyme, or transporter, but primarily a cell cycle/tumor suppressor and stress response protein, with notable roles in cancer biology and cell differentiation.

Other names

HECAHDChHDCHDCLdJ225E12.1Headcase protein homologHeadcase homologHHDC

No drugs directly targeting HECA have known mechanisms; its studied biological mechanism is tumor suppression through cell cycle arrest and stress granule regulation